|
|||||
|
|
| 阿德福韦酯单用或联合拉米夫定治疗耐药性慢性乙型肝炎 | |
| 引用本文： | 万学发,万秭新,张黎明,诸葛传德.阿德福韦酯单用或联合拉米夫定治疗耐药性慢性乙型肝炎[J].中华医院感染学杂志,2010,20(6). |
| 作者姓名： | 万学发 万秭新 张黎明 诸葛传德 |
| 作者单位： | 1. 台州中心医院感染科,浙江,台州,318000 2. 浙江省海正药业股份有限公司,浙江,台州,318000 3. 上海瑞金医院感染科,上海,240002 |
| 摘 要： | 目的观察阿德福韦酯单用或联合拉米夫定治疗耐药慢性乙型肝炎(YMDD变异)的临床疗效。方法拉米夫定耐药慢性乙型肝炎患者60例(YMDD变异)分A组30例(阿德福韦酯10 mg 1次/d;拉米夫定100 mg 1次/d连续72周),B组30例(单用阿德福韦酯,方法剂量同A组);动态观察患者血清HBV DNA、HBeAg/HBeAb和肝功能变化。结果A组HBV DNA阴转率在12、24、48、72周时分别为36.7%、43.3%、53.3%、76.7%;B组分别为33.3%、46.7%、63.3%、56.7%,但两组之间比较在72周时差异有统计学意义(χ2=2.297,P0.05);A组HBeA阴转率在72周时A组明显高于B组(χ2=1.534,P0.05);A,B两组ALT复常率比较在12周时A组明显高于B组(χ2=2.703,P0.05)。结论阿德福韦酯单独或联合拉米夫定,对拉米夫定耐药的慢性乙型肝炎均有治疗作用;联合用药效果更好。 |
| 关 键 词： | 阿德福韦酯 拉米夫定 HBeAg阳性 慢性乙型肝炎 抗药性 变异 |
Adefovir Dipivoxil alone or in Combination with Lamivudine in Treatment of Lamivudine-resistant HBeAg-positive Chronic Hepatitis B |
|
| WAN xue-fa,WAN Zi-xin,ZHANG Li-ming,ZHUGE Chuan-de.Adefovir Dipivoxil alone or in Combination with Lamivudine in Treatment of Lamivudine-resistant HBeAg-positive Chronic Hepatitis B[J].Chinese Journal of Nosocomiology,2010,20(6). | |
| Authors: | WAN xue-fa WAN Zi-xin ZHANG Li-ming ZHUGE Chuan-de |
| Institution: | WAN Xue-fa,WAN Zi-xin,ZHANG Li-ming,ZHUGE Chuan-de(Taizhou Central Hospital,Taizhou,Zhejiang 318000,China) |
| Abstract: | OBJECTIVE To survey the therapeutic effect of adefovir dipivoxil alone or in combination with lamiudine in the treatment of lamivudine-resistant HBeAg-positive chronical hepatitis B(YMDD mutant).METHODS Sixty patients with lamivudine-resistant HBeAg-positive chronic hepatitis B were divided into two groups:A and,B.The patients of group A(n=30) were given each 10mg adefovir dipivoxil po qd,in the meantime,each of them was given 100mg of lamiudine po,qd,for 72weeks.Patients of group B(n=30) were subjected to ... |
| Keywords: | Adefovir dipivoxil Lamifudine HBeAg-positive Chronic viral hepatitis B Drug resistance Mutation |
| 本文献已被 CNKI 万方数据 等数据库收录！ | |